First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (FBT) Competitors

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) and The Sage Group (LON:SGE) are both computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, community ranking, earnings, institutional ownership, risk and profitability.

Is FBT or SGE more profitable?

The Sage Group has a net margin of 11.87% compared to First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's net margin of 0.00%. The Sage Group's return on equity of 22.31% beat First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation	N/A	N/A	N/A
The Sage Group	11.87%	22.31%	7.58%

Do analysts prefer FBT or SGE?

The Sage Group has a consensus price target of GBX 3,446.67, indicating a potential upside of 159.21%. Given The Sage Group's stronger consensus rating and higher probable upside, analysts plainly believe The Sage Group is more favorable than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
The Sage Group	2 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.14

Does the media prefer FBT or SGE?

In the previous week, The Sage Group had 6 more articles in the media than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. MarketBeat recorded 6 mentions for The Sage Group and 0 mentions for First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's average media sentiment score of 1.60 beat The Sage Group's score of 0.00 indicating that First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is being referred to more favorably in the media.

Company	Overall Sentiment
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation	Very Positive
The Sage Group	Neutral

Does the MarketBeat Community prefer FBT or SGE?

The Sage Group received 454 more outperform votes than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation when rated by MarketBeat users. However, 66.67% of users gave First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation an outperform vote while only 44.96% of users gave The Sage Group an outperform vote.

Company	Underperform	Outperform
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation	Outperform Votes 72 66.67%	Underperform Votes 36 33.33%
The Sage Group	Outperform Votes 526 44.96%	Underperform Votes 644 55.04%

Which has preferable earnings & valuation, FBT or SGE?

The Sage Group has higher revenue and earnings than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than The Sage Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation	£870.31K	6,029.84	N/A	-£1.10	-1,614.55
The Sage Group	£2.25B	5.89	£267M	£0.26	5,114.15

Do insiders and institutionals believe in FBT or SGE?

67.0% of The Sage Group shares are owned by institutional investors. 1.1% of The Sage Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

The Sage Group beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 13 of the 16 factors compared between the two stocks.